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Abstract 
Background: Multiple Sclerosis (MS) patients are faced with complex risk-benefit profiles of disease-modifying drugs 
(DMDs) when making treatment decisions. For effective shared decision-making, MS patients should understand the 
risks and benefits of DMDs and make treatment decisions based on personal preferences. 
Methods: This is an inclusive systematic review to primarily assess current understanding of MS patients for 
information about DMDs provided during the standard healthcare system. The secondary aim assesses MS patients’ 
preferences for specific risks and benefits of treatments. A systematic search was conducted using PubMed, Embase 
and Google Scholar. A total of 22 studies were reviewed across both aims. Relevant quantitative and qualitative data 
was extracted by two authors. A narrative synthesis was conducted due to heterogeneity of research findings. 
Results: There was a trend for DMD risks to be generally underestimated and DMD benefits to be generally 
overestimated by MS patients. Treatments that could potentially offer substantial symptom improvement, delay in 
disease progression, or reduction in relapses were preferred even at the expense of higher risks. 
Conclusions: Many patients’ experience of information during the standard healthcare system does not provide 
satisfactory understanding of the risks and benefits of DMDs. Effective ways to communicate risk and benefit DMD 
information when making shared treatment decisions needs to be identified. Patient preferences of DMD risks and 
benefits should also be taken into account. 
Keywords 
Multiple Sclerosis, disease-modifying drugs, understanding, preferences, systematic review, shared decision-making 
 
 
 
 
 
 
Page | 3 
 
1. Introduction  
Multiple sclerosis (MS) is a chronic immunological disease of the central nervous system which progresses at 
different rates between individuals [1,2]. Disease-modifying drugs (DMDs) are treatments which can delay the 
progression of MS, but often present complex profiles of risks and benefits [3]. DMDs typically provided at the earlier 
stages of MS are selected for their long-term safety profiles and minimal monitoring requirements, and are generally 
referred to as first-line treatments [4]. The efficacy of these therapies are modest [5]. More aggressive DMDs may be 
considered when initial therapies are not effective. These DMDs generally offer superior efficacy but also higher 
probabilities of adverse effects, which can range from flu-like symptoms to fatal conditions such as leukemia or 
progressive multifocal leukoencephalopathy (PML) [3,6–9]. MS patients are thus faced with complex risk-benefit 
profiles when deciding on the best course of treatment. 
A shared decision-making approach is particularly suited for a chronic condition such as MS, where there is great 
complexity and uncertainty about suitable treatments for an individual [10,11]. This approach is defined as the 
shared and proactive exchange of information between health professionals and patients, when making treatment 
decisions during consultations [12–14]. Effective shared decision-making in MS should improve patients’ 
understanding of the risks and benefits of DMDs and allow patients to make treatment decisions in accordance with 
their personal values, which will likely improve patient engagement in the decision-making process [15,16]. 
Evidence-based information about DMDs should be effectively communicated during consultations based on the 
shared decision-making approach, since many MS patients seek autonomy during treatment decisions [17,18]. 
Autonomous patients desire accurate information about treatments, which includes current research findings about 
DMD risks and benefits [19,20]. If accurate information is not provided during consultations, it is likely that 
autonomous patients will seek information beyond the health care system that may be inaccurate or outdated. The 
benefits of providing clear and accurate treatment information to patients is also evident beyond initial treatment 
decision. One such benefit is improvement in treatment adherence, as patients with accurate understanding of 
treatment risk-benefit profiles are less likely to discontinue treatment due to unrealistic optimistic expectations 
[21,22]. Hence, it is important to determine whether MS patients sufficiently understand the complex risk-benefit 
profiles of DMDs when information is provided during the standard healthcare system.  
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It is also important to elicit patient values and preferences in order for shared decision-making to work effectively 
[16]. Patient preference in the shared decision-making context is generally defined as patient’s choice of treatment 
based on available treatment options [14,23]. Preference for certain risks and benefits that treatments offer may be 
a sensitive predictor of patient’s preferred choice of treatment. For instance, patients are likely to choose a 
treatment compatible with the level of risks they are willing to take [24,25] and may be more likely to forgo the 
benefits of long-term survival for the benefits of an improved quality of life [26]. In a recent review, MS patients’ 
perception of treatment risks was also found to greatly impact patients’ treatment decisions with their neurologists 
during the shared decision-making process [27]. For this reason, it is important to identify the extent to which 
patient preferences for both the risks and benefits that DMDs typically offer can influence MS patients’ treatment 
decision. 
To the best of our knowledge, the present systematic review is the first to gather evidence on MS patients’ 
understanding and preferences for risks and benefits of treatments. The primary aim will evaluate MS patients’ 
understanding of risk and benefit information for DMDs acquired during their journey through standard healthcare 
systems, preceding any interventions or decision aids that may be provided beyond regular consultations. The 
secondary aim will identify MS patients’ preferences for treatment risks and benefits across studies, and assess 
whether these preferences can have an impact on patient’s treatment decisions.  
2. Method 
2.1. Systematic literature search 
The systematic literature search was conducted in February 2016 through PubMed, Embase and Google Scholar 
using specific search terms for both study aims (see Table 1). After removing duplicate entries, a total of 889 records 
were identified (see figure 1). 
Studies were eligible for inclusion if they were: in English, with human adults and of any study design. Studies with 
patients of any MS disease subtype were included. No date restriction was applied. For both aims, studies were 
included if they had some evaluation of disease-modifying drugs and when the evaluations focused on patients with 
MS.  
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Studies were excluded if they discussed medications for MS symptom management or complementary medicines. 
Studies with evaluation of patients’ understanding of disease-modifying drugs post educational intervention was not 
included. However, baseline measures prior to any educational intervention were eligible for inclusion in the present 
review. Studies that assessed MS patients’ understanding for other areas in MS, including diagnosis and prognosis, 
were excluded. Studies focusing only on patients’ adherence to DMDs were also excluded.  
Following screening of titles and abstracts, 835 records were excluded. Full texts were subsequently accessed. 
Studies that were considered relevant from screening references were also identified. Thus, data was extracted for a 
total of 58 full-texts, and studies were included into the final review if inclusion and exclusion criteria were met (see 
figure 1).  
2.2. Data extraction 
Data extraction was carried out by one reviewer (GR) using data extraction forms specifically designed for the 
current review, and was verified by another (DL). Any discrepancies were resolved by discussion. After extraction of 
full texts, a total of 22 studies were included into the final review across both study aims. One study had relevant 
findings for both the primary aim and secondary aim. Thus, 14 studies were included into the primary aim and 9 
studies were included into the secondary aim. 
Baseline characteristics of MS patients were extracted from all 22 studies, which covered age, the type of MS and 
current DMD status. Since very few studies exclusively assessed understanding or preferences of treatment risks and 
benefits in MS, studies with any evaluation of either aims were retained.  
For the primary aim, any data available on understanding of treatment risks or benefits, or understanding of the 
treatment overall, was retained. Only understanding of information about real DMDs was incorporated into this aim. 
This information sometimes existed as baseline measures in intervention studies. Both self-report and objective 
measures were included for review, in addition to themes from qualitative studies.  
For the secondary aim, patients’ preferences for treatment risks only, treatment benefits only and a combined trade-
off between treatment risks and benefits were considered. Preferences for treatment risks and benefits were 
defined as patients’ attitudes towards risks and benefits, the levels of risks and benefits MS patients were willing to 
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accept, or MS patients’ perception of their current DMD. Preferences for risks and benefits of both real DMDs and 
hypothetical treatment scenarios were included in this aim, providing that hypothetical risk-benefit scenarios were 
relevant to MS. Similar to the primary aim, information from self-report and objective measures were discussed. 
Relevant data was obtained from numerical information in texts, tables, graphs, and relevant statistical analysis. For 
qualitative studies, relevant themes were extracted and discussed. Medication names are given as reported in each 
study. Due to the heterogeneity of the studies in the present review, a narrative synthesis was conducted.  
2.3. Quality assessment 
All studies in this review were examined independently for quality by two reviewers (GR and DL) using the Effective 
Public Health Practice Project (EPHPP) quality assessment tool for quantitative studies [28]. This particular tool was 
chosen because it is often used to evaluate different types of quantitative studies in the health care setting [29], it 
has high inter-rater reliability [29] and is considered ideal for use in systematic reviews [30]. As per the tool, the final 
quality rating was derived from the rating of 6 measures (see tables 2 and 4).  
The Critical Appraisal Skills Programme (CASP) tool was used to appraise the quality of qualitative studies in this 
review (see table 3). This tool was chosen as it has often been recommended for reviewers [31] and was previously 
used in other systematic reviews [32]  
3. Results 
3.1. Results: Primary aim 
3.1.1. Patient and study characteristics 
A total of 14 studies were included in the primary aim (see table 5 and 6). With the exception of three qualitative 
studies [33–35], the studies mostly consisted of surveys and questionnaires. Data from some studies was derived 
from baseline measures of randomised-controlled trials [36–38]. Two quantitative studies were found to have the 
strongest quality rating [36,39]. 
Across the 14 studies, a total 8032 patients were included with a range of MS disease subtypes, which comprised: 27 
(0.3%) patients with Clinically Isolated Syndrome (CIS), 2,532 (31.5%) Relapsing-remitting MS (RRMS) patients, 349 
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(4.3%) Primary Progressive MS (PPMS) patients and 870 (10.8%) Secondary Progressive MS (SPMS) patients. Of the 
remaining, 251(3.1%) patients were reported as having benign MS, with unclear or unreported MS disease subtype 
for all other MS patients (49.8%). The mean age of patients was 42 (range: 34 – 50). The mean value excludes MS 
patients in studies that only stated the median values of age [40], the range of ages [34,35] and those studies that 
did not specify age of MS patients [36,41]. 
Of the studies which recorded patient’s current DMD, the majority of patients were taking first-line treatments, 
including interferons in seven studies [34,36,38,41–44] and Glatiramer acetate in four studies [35,38,41,42]. MS 
patients taking aggressive medications were also recorded, including Natalizumab (Miller et al., 2012), Fingolimod 
[37] and Mitoxantrone [41,45]. Eight studies focused primarily on MS patients taking a single DMD [33–37,43–45] 
3.1.2. Study outcomes 
Understanding of overall treatment information 
MS patients’ understanding of overall DMD information during the routine healthcare system was assessed using 
questionnaires and surveys by seven studies. 
Self-report measures in one study indicated that 44% of MS patients considered themselves extremely well-
informed about their current DMD [43]. Using a visual analogue scale in another study, just under 20% of patients 
reported being fully informed about current DMDs [37]. Using retrospective surveys, 28% of patients reported being 
well-informed about DMDs at time of diagnosis, with just over 50% patients stating that they did not receive any 
information about DMDs at diagnosis [46]. On the other hand, between 75% to 84% of MS patients reported being 
partly or totally informed about current DMDs [40,42], and 85% of MS patients felt they were aware about other 
DMD treatment options based on one question from a 12-item questionnaire [41]. Of those patients who felt 
informed about DMDs, 71% of MS patients felt the information received was of a sufficient standard [46]. 
Objective measurements were used by two studies within the present review to establish MS patients’ 
understanding of overall treatment information. Abolfazli and colleagues [44] administered a 25-item questionnaire 
to MS patients, nine questions of which assessed understanding of the first-line treatments in general, and three 
questions each focused on understanding of the five specific DMDs that fell within this category. Only 30% of MS 
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patients were able to correctly answer seven of the nine questions that assessed understanding of the drugs 
generally, with the remaining two questions answered correctly by just over 60% of MS patients. The authors 
concluded that understanding of overall information about first-line DMDs was low for the assessed MS patients 
[44]. Another study also employed an objective questionnaire, which was presented to patients as part of a baseline 
measure before intervention [37]. MS patients in this study answered a median of six questions correctly about 
overall understanding of their current DMD from a maximum score of 18 [37]. Both studies also analysed factors 
which were associated with greater understanding by MS patients for overall information about DMDs.  A common 
significant patient factor associated with better understanding across both studies was gender, since females 
displayed greater understanding of overall information about first-line DMDs [44] and the more aggressive 
treatment Fingolimod [37]. Greater understanding of overall DMD information was also related to: a high level of 
education [44], the delay between onset of symptoms and diagnosis of MS [44], increased mobility [44], younger age 
[44], ability to self-inject for some first-line treatments [44] and patients who were in a relationship as opposed to 
being single [37]. 
In summary, majority of studies which assessed MS patients’ understanding of overall DMD information relied 
heavily on patient self-reports. Although the findings varied both within and across studies, it is clear that not all 
patients feel sufficiently informed about DMDs during the routine healthcare system. This is also supported by 
objective measures, albeit in only a few studies. The factors associated with good understanding of overall DMD 
information were also inconsistent, with only females showing a consistent advantage across two studies.  
Understanding of treatment risks.  
MS patients’ understanding of treatment risks was evaluated by four studies in this review.  
Perceived accurate understanding of the risks of unspecified DMDs was reported by 63% of MS patients in one study 
[18]. A qualitative study interviewing MS patients taking the aggressive treatment Natalizumab showed mixed 
findings for understanding of the risks associated with this treatment; patients demonstrated both high and low 
perceived risk [33]. 
Three studies used objective questionnaires to assess understanding of DMD risks, with two of these studies 
administering a similar adapted 19-item questionnaire designed for newly diagnosed patients [18,38]. Approximately 
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30% of MS patients showed ‘good risk knowledge’ for their DMD based on their scores from this questionnaire [38]. 
For the other study employing a similar questionnaire, MS patients were only able to answer 34% of the questions 
correctly on average despite perceiving their risk knowledge as good [18]. Significant correlations were also 
established between greater understanding of DMD risks and patients who had been recently diagnosed, had the 
RRMS disease subtype, and were of a younger age [18]. To note, questionnaires employed in both studies primarily 
measured understanding of the risks associated with MS in general, with only a portion of the questions explicitly 
focusing on risk understanding of DMDs. In another study employing objective methodology for the understanding 
of the aggressive DMD Mitoxantrone, 55% of MS patients underestimated the risk of Leukaemia, and up to 82% of 
MS patients underestimated the risk of cardiotoxicity; both adverse risks associated with this DMD [45]. These 
findings were based on baseline measures of an interventional study [45]. 
In summary, although MS patients show mixed perception towards their understanding of DMD risks, objective 
measures seem to indicate that DMD risks are generally low and underestimated by MS patients during the routine 
healthcare system. 
Understanding of treatment benefits.  
MS patients’ understanding of the benefits associated with their treatment was evaluated by five studies in the 
present review. 
 Over 70% of MS patients taking a range of DMDs believed their current DMD could help their MS [41]. Likewise, a 
large number of MS patients totally or partially perceived their current medication to have strong benefits: 90% of 
MS patients perceived that their DMD could reduce the frequency of MS relapses, 86% of MS patients believed that 
their current medication could delay the progression of disease and just over 70% of MS patients were generally 
optimistic about their condition as a result of taking their current medication [42]. In two qualitative studies, MS 
patients taking first-line treatments described their medication as a “saviour” [34] and believed that taking the DMD 
felt as if they were “doing something progressive” towards their condition [35].  
Only one early study employed an objective methodology to measure understanding of DMD benefits. Mohr and 
colleagues [36] administered a 12-item questionnaire prior to providing an intervention. Only 39% of MS patients 
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accurately reported the benefits of taking their first-line DMD, and 57% of MS patients were found to optimistically 
and incorrectly state that MS relapses could be reduced by a half following uptake of their current DMD [36]. 
Acknowledging the difficulty in comparing studies with self-report and objective measures, and those encompassing 
MS patients taking a range of DMDs, the limited data in the current review indicates a general trend towards 
underestimation of treatment risks and overestimation of treatment benefits by MS patients during the routine 
healthcare system. 
3.1. Results: Secondary aim 
3.1.1. Patient and study characteristics 
The studies in this part of the review consisted mostly of surveys and questionnaires (see table 7). One study that 
has previously been reviewed in the primary aim also included findings relevant to the secondary aim [44].  Only one 
study in this section of the review was found to have the strongest quality rating [47]. 
From the final 9 studies included into the secondary aim, a total of 7427 patients were included with a range of MS 
disease subtypes, comprising of: 45 (0.6%) CIS patients, 652 (8.4%) RRMS patients, 31 (0.4%) PPMS patients and 59 
(0.8%) SPMS patients. Majority of the studies did not clearly report or specify the MS disease subtype (89.8%). The 
mean age of MS patients was 42 (range: 34 – 52). 
Of the studies which reported the current DMDs of MS patients, majority reported patients taking first-line 
treatments, which includes interferons in five studies [44,48–51] and Glatiramer acetate in four studies [48–51]. 
Patients taking more aggressive DMDs also formed a part of this review, specifically patients taking Natalizumab [49–
52], Fingolimod [50,51] and Rituximab [50]. Two studies focused primarily on a single DMD [44,52]. 
3.1.2. Study outcomes 
Preferences for treatment risks.  
Four studies, each employing objective methodologies, looked at MS patients’ preferences for the risks of taking a 
treatment.  
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Tur and colleagues [49] assessed the level of risks that MS patients were willing to accept for hypothetical 
therapeutic scenarios. The authors also assessed the relationship between accepted levels of hypothetical treatment 
risks and current DMDs taken by MS patients. A visual analogue scale showed that MS patients on the aggressive 
treatment Natalizumab were willing to accept higher levels of hypothetical treatment risks in comparison to MS 
patients on any other DMD [49].  
Hypothetical treatment scenarios were employed by two further studies using objective methodologies, which 
compared MS patients’ preferences for different levels of treatment risks [50,51]. Both studies confirmed that DMDs 
with significant adverse side-effects were less preferred than DMDs with minor side-effects. In fact, both studies 
revealed that medications with no possibility of death or disability were significantly favoured to a medication with 
even a very low possibility (0.05% to 1%) of death or disability [50,51]. Mood changes were the only specific side-
effect that would decrease the probability of taking a DMD by MS patients [50,51]. 
Using a standard gamble question task, another study employed a hypothetical treatment scenario which presented 
information about a treatment that could cure MS, and a real treatment scenario which presented the risk profile of 
the aggressive DMD Natalizumab [53]. MS patients showed similar preferences for risks in both the hypothetical and 
real treatment risk scenarios, as adverse risks were accepted when in the range of 1 in 10,000 [53]. For the 
hypothetical treatment scenario, MS patients that were significantly likely to prefer higher levels of adverse risks 
were those presenting with the following characteristics: wheelchair bound, male, not responsible for dependents, 
not currently taking a DMD, taking Natalizumab and not routinely wearing a seatbelt for car travel [53]. With the 
exception of MS patients who were not taking a DMD, the same characteristics of MS patients preferred higher 
levels of treatment risks in the real DMD scenario [53].  
Despite the comparison of hypothetical and real treatment risk profiles in this section of the review, MS patients 
showed similar low preferences for treatment risks. 
Preferences for treatment benefits.  
MS patients’ preferences for treatment benefits were assessed by five studies in the present review. 
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Two studies used subjective measures to assess the preferences of MS patients towards treatment benefits [44,47]. 
MS patients with a positive outlook towards their current DMD ranged from 20% to 90% within one study [44] and 
was approximately averaged at 60% in another [47]. Patient factors significantly associated with a positive attitude 
were patients with: lack of functional problem, no MS family history and knowledge of their current DMDs [44].  
Turning to objective measures, Prosser and colleagues [48] utilised a gamble health outcomes task using 
hypothetical treatment scenarios to assess preferences of MS patients for treatment benefits. During this task, 
patients were required to choose either a drug offering a particular number of relapse-free days, or a drug offering a 
50% chance of ending the MS relapse immediately but with 50% chance of the drug not working at all. On average, 
patients chose drugs likely to lead to 14.6 MS relapse-free days from the possible 29, implying a preference towards 
treatments offering moderate but guaranteed benefits. However, the authors did note that approximately 30% of 
MS patients chose an extreme number of relapse-free days, i.e. either 1 or 29 [48]. 
The frequency of MS relapses was also used as an outcome measure to assess MS patients’ preferences for 
treatment benefits in the remaining two studies and was compared alongside other benefits that DMDs typically 
offer [50,51]. The highest preference for MS patients in one study was for substantial symptom improvement in MS, 
followed by prevention of disease progression over 10 years, mild symptom improvement and a five-year delay in 
MS relapses [51]. Administration in the form of an IV infusion or oral pill was also significantly preferred by MS 
patients. In fact, the ability to administer the drug orally was preferred even over a five-year delay in relapse [51].  
Likewise, any form of improvement in symptoms and the ability to take the drug orally were also strongly preferred 
by MS patients in the latter study [50]. However, unlike the previous findings, MS patients in this study showed no 
significant preference for delay in MS relapses or administration of drugs via IV infusion [50]. Additionally, the ability 
to prevent MRI progression over the years was used as an indicator only in this study and was significantly preferred 
by MS patients [50].  
Although all studies in this review assess MS patients’ preferences for treatment benefits, chiefly for hypothetical 
treatment scenarios, the results are not directly equivalent as the range and actual treatment benefits offered to 
patients differed greatly between studies. In general, treatments offering high symptom improvement, a delay in 
disease progression, reduction in relapses and particular administration methods were preferred. 
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Preferences for treatment risk-benefit profiles.  
Three studies objectively measured the risk-benefit trade-off by offering MS patients the choice of benefits and risks 
for hypothetical treatments, using the conjoint analysis method [50–52]. Whilst all three studies used a similar 
objective methodology, the studies employed different treatment risk and benefit scenarios. Johnson and colleagues 
[52] demonstrated that for a five-year delay of disease progression, a 0.48% risk of death by Leukaemia was 
acceptable for MS patients; which increased to 1.08% for an eight-year delay of disease progression. For a similar 
delay of disease progression, the acceptable risk of death by liver failure increased by 0.53%, and acceptable risk of 
severe disability or death from PML increased by 0.36% [52]. Wilson and colleagues [51] found that patients were 
willing to accept 0.7% risk of developing PML given a delay in the progression of disease [51]. Up to 1% adverse risks 
were accepted by MS patients if substantial improvements in symptoms could be demonstrated by the treatment 
[51]. Patients were willing to accept up to 0.59% of severe adverse effects if drugs could be administered orally [51]. 
In fact, this level of risk acceptance was higher than for drugs which could delay the progression of MS by four years 
[51] or could reduce the frequency of MS relapses from four yearly to no relapses within the next five years [52]. 
Further, a risk of up to 30% of severe adverse effects was acceptable for MS patients given 32 years of delay in 
progression of MS [50].  
The study by Bruce and colleagues also assessed risk and benefit trade-offs of hypothetical treatment scenarios, by 
using a Medical Decision Making Questionnaire (MDMQ) [54]. Similar to previous studies, the choice of whether to 
uptake a treatment for all patients differed significantly according to the combination of treatment risks and benefits 
[54]. Additionally, patients who were adherent to their current unspecified treatment were willing to take 
medications with significantly higher combinations of risks and benefits than patients who were assessed as non-
adherent [54]. 
In summary, despite using similar measures to objectively assess trade-offs of treatment risks and benefits, the three 
studies employed very different combinations of risks and benefits, limiting any generalised conclusions that may be 
based on these findings. However, it was clear from these studies that preferred combinations of treatment risks 
and benefits play a key role in the choice of treatment.   
4. Discussion and Conclusion 
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4.1. Discussion 
This systematic review was carried out to explore MS patient’s understanding of DMD risks and benefits acquired 
through their standard healthcare systems, and MS patients’ preferences for these risks and benefits; factors likely 
to impact shared decision-making. MS patients with different disease subtypes and those taking a range of DMDs 
were assessed by 22 studies in the present review. Understanding of DMD risks and benefits were mostly addressed 
as part of a larger project. MS patients’ preferences for risks and benefits were generally assessed using treatments 
offering hypothetical risks and benefits. Studies employed both subjective and objective measures. The majority of 
studies had methodologies that precluded firm conclusions. 
DMDs in MS have complex risk-benefit profiles. All DMDs offer benefits of varying levels, such as reduction in the 
frequency of MS relapses and delay in progression of the disease. Side-effects of treatments can range from mild 
symptoms to adverse effects that may lead to severe disability or death [3]. When making decisions about DMDs 
based on these complex risk-benefits, a shared decision-making approach is ideal.  
For effective shared decision-making, clear and accurate DMD information should be provided to MS patients in 
order to facilitate understanding of treatment risks and benefits. Yet, it appears from the present review that MS 
patients do not sufficiently understand information about DMDs following routine consultations in their standard 
healthcare system. Despite evaluating their risk knowledge as high [18], MS patients in this review showed poor 
objective risk understanding [18,38]. There was a trend towards underestimation of treatment risks [41,45]. This is 
problematic for long-term treatment adherence, as some patients are more likely to initiate a treatment that they 
perceive has lower risks but then discontinue treatment when the risks are higher than initially expected [19,22]. MS 
patients in this review were generally optimistic about the benefits of their current DMD [33,34,41,47]. However, 
many patients overestimated the benefits of their DMD in reducing the frequency of relapses and delaying 
progression of disease [36,42]. This could mean that patients’ optimism towards DMDs may not often accurately 
reflect the actual benefits of the drugs. This can further impact treatment adherence, since patients who do not 
accurately understand the benefits of DMDs are more likely to discontinue treatments overtime [22], perhaps as 
optimism for medications is replaced with the realisation that the medication does not offer expected levels of 
benefits. In fact, a significant relationship between patients who understand information about their treatments and 
their adherence to treatments is evident in several studies, including those in the present review [21,22,39,42]. 
Page | 15 
 
Providing accurate and easily understandable risk and benefit information to MS patients should therefore improve 
treatment adherence towards their chosen treatment.  
The ability to understand overall information about DMDs provided during the standard healthcare system was 
found to be associated with certain patient factors, for example: age, education and functional status [37,44]. It is 
also possible that symptoms of MS itself, for example depression [55], anxiety [56], fatigue [57] and cognitive 
impairments [58,59], may further confound understanding of information about DMDs. However, these symptoms 
were not explored within the studies in this review. Regardless, it is apparent that some MS patients require further 
support to comprehend treatment information to a good standard. This may explain what prompts many patients to 
independently seek treatment data through sources beyond standard healthcare [19,42,43]. This external treatment 
information may not necessarily be accurate or up-to-date and could lead to further misunderstanding. Thus future 
studies need to primarily focus on improving the existing methods of providing DMD information for all MS patients, 
in order to improve shared decision-making.  
Effective shared decision-making also requires patients to communicate their preference for a particular treatment. 
Preferences specifically for risks and benefits of DMDs are likely to influence MS patients’ treatment choice [24–26]. 
The secondary aim of the present review assessed the extent to which preferences towards risks and benefits that 
DMDs typically offer can impact MS patients’ treatment decisions. As anticipated, even very low levels of adverse 
risks reduced patients’ preference to take the treatment, and extremely small variations in risk had a significant 
impact on hypothetical treatment decisions [50,51,53]. Preference for medications with adverse risks rarely 
exceeded 1%.  Preferences for risks also varied with certain patient factors, as higher risks were generally accepted 
by males, functionally impaired individuals, or people already taking aggressive treatments such as Natalizumab 
[49,53]. Similarly, certain benefits that DMDs typically offer were significantly preferred over others and had an 
impact on the choice of treatment. Remarkably, patients strongly favoured medications that could provide symptom 
improvement [50,51], which implies limited understanding for MS treatments since DMDs are not able to relieve 
symptoms of MS. To note, medications presented in both studies [50,51] employed hypothetical treatment 
scenarios and therefore it is plausible that patients perceived symptom improvement as hypothetical despite 
accurate understanding of DMD benefits [50,51]. It is nevertheless interesting that patients are likely to take higher 
risks if DMDs can seemingly aid symptoms of their condition. MS patients in this review also showed a greater 
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preference for treatments offering large reductions in frequencies of relapses, longer delay in disease progression 
and drugs that could be administered orally, being prepared to accept a greater likelihood of risk in return [50–
52,54]. Overall, MS patient preferences varied according to different combinations of particular risks and benefits, 
and had a significant impact on their choice of treatment. Thus, it is important to elicit patient preferences for 
particular risks and benefits of DMDs in order to improve shared decision-making in MS. 
A limitation of the present systematic review is the difficulty in drawing robust conclusions or conducting a meta-
analysis of the studies as a result of the variety of outcome measures employed. A narrative synthesis was 
considered to be the most appropriate format for reviewing the studies. However, it is important to acknowledge 
that such a qualitative review is subject to greater analysis bias than a quantitative systematic review. There were 
also differences in study design, methodology and patient characteristics between studies in the review, which limits 
conclusions from such findings. This reflects the lack of uniformity across studies that address MS patients’ 
understanding of medications. The present review also does not constitute an exhaustive search of studies or 
research findings; for example, the primary authors of studies were not contacted to resolve or expand on study 
findings owing to time and resource constraints. However, it seems unlikely that supplementary results or additional 
outcome measures could produce less heterogeneous results.  
4.2. Conclusion 
The present review was the first to our knowledge to systematically gather evidence about patients’ understanding 
of the risks and benefits of DMD during their standard healthcare system, and their preferences for these risks and 
benefits; factors which can likely impact shared decision-making. Despite the heterogeneous findings, it seems that 
current ways of providing DMD risk and benefit information are not generally uniform or effective. MS patients tend 
to underestimate treatment risks and overestimate treatment benefits, with some patients finding comprehension 
especially difficult. MS patients prefer treatments offering extremely low levels of adverse risks, but are willing to 
accept higher risks in exchange for substantial long-term improvements. 
Practical implications of this review are providing extra support to ensure all patients are effectively informed about 
the complex risk-benefit profiles of MS DMDs, and ensuring patients’ preferences for treatment risks and benefits 
are taken into account during the shared decision-making process. 
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Figure 1. Flow diagram for included studies: Primary aim and secondary aim 
 
835 
Records excluded following 
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Studies included 
889 
Records Identified through 
database searching (duplicates 
removed) 
36 
Full-texts excluded: 
 
Review (n=9) 
Patient understanding for 
other aspects of MS (n=8) 
Other MS medications (n=4) 
Diagnosis and prognosis of 
MS (n=5) 
Patient understanding of 
DMD information after 
intervention (n=4) 
DMD adherence (n=5) 
Secondary data for study 
included in present review 
(n=1) 
7 
Additional records 
identified through other 
sources 
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Table 1. Search terms for Systematic review: Primary aim and secondary aim 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Search terms for Systematic Review 
 
(Multiple AND Sclerosis) 
AND 
(patients OR people OR persons OR patient) 
AND 
(risk OR benefit OR side effect) 
AND  
(treatment OR medication OR therapy OR medicine OR 
medical OR therapies OR therapeutics OR Pharmaceutical 
preparations) 
AND 
(perception OR understanding OR comprehension OR 
awareness OR knowledge OR information OR 
communication OR preference OR decision-making) 
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Table 2. Quality assessment of studies investigating MS patients’ understanding of DMD risks and benefits: Primary aim 
 
Overall quality rating: Strong=no weak ratings; Moderate=one weak rating; Weak=two or more weak ratings. 
 
 
 
First author 
(year) 
Selection bias Study design Confounders Blinding Data collection 
method 
Withdrawals and dropout Overall quality rating 
Mohr (1996) Moderate Moderate - Moderate Strong Strong Strong 
Heesen (2003) Weak Weak - Moderate Weak Weak Weak 
Heesen (2004) Moderate Weak - Moderate Strong Moderate Moderate 
Vlahiotis 
(2010) 
Weak Weak - Moderate Moderate Weak Weak 
Visser (2011) Weak Moderate - Moderate Weak Moderate Weak 
de Seze (2012) Weak Weak - Moderate Strong Weak Weak 
Hofmann 
(2012) 
Weak Moderate - Moderate Weak Weak Weak 
Kopke (2014) Strong Strong Strong Strong Strong Strong Strong 
Syed (2014) Weak Moderate - Moderate Moderate Weak Weak 
Abolfazli (2014) Weak Weak - Moderate Weak Strong Weak 
Zimmer (2015) Moderate Moderate - Moderate Moderate Strong Moderate 
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Table 3. Quality assessment of qualitative studies investigating MS patients’ understanding of DMD risks and benefits: Primary aim 
 
Quality assessed using the Critical Appraisal Skills Programme tool (CASP); all categories marked as either Yes, No or Can’t tell/unclear. 
 
 
 
 
 
 
 
 
 
First author 
(year) 
Clear 
aims 
Appropriate 
methodology 
Appropriate 
design 
Appropriate 
recruitment 
strategy 
Data 
collection 
method 
Researcher 
and 
participant 
relationship 
considered 
Ethical 
issues 
considered 
Rigorous 
data 
analysis 
Statement 
of findings 
Is the 
research 
valuable? 
Miller 
(2001) 
Yes Yes Yes Yes Yes No Unclear Yes Yes Yes 
Miller 
(2006) 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Miller 
(2012) 
Yes Yes Yes Yes Unclear Yes Unclear Yes Yes Yes 
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Table 4. Quality assessment of studies investigating MS patients’ preferences for treatment risks and benefits: Secondary aim. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overall quality rating: Strong=no weak ratings; Moderate=one weak rating; Weak=two or more weak ratings 
 
 
 
 
 
First author 
(year) 
Selection bias Study design Confounders Blinding Data collection 
method 
Withdrawals and dropout Overall quality rating 
Prosser (2002) Moderate Weak - Moderate Strong Strong Moderate 
Kasper (2008) Strong Strong Strong Strong Moderate Strong Strong 
Johnson (2009) Weak Weak - Moderate Strong Strong Weak 
Tur (2013) Moderate Moderate Moderate Weak Moderate Strong Moderate 
Abolfazli (2014) Weak Weak - Moderate Weak Strong Weak 
Wilson (2014) Moderate Weak - Moderate Moderate Moderate Moderate 
Bruce (2015) Moderate Weak - Moderate Moderate Weak Weak 
Fox (2015) Weak Weak - Moderate  Moderate Weak Weak 
Wilson (2015) Moderate Weak - Moderate Weak Strong Weak 
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Table 5. Patient and study characteristics, and results of quantitative studies investigating MS patients’ understanding of DMD risks and benefits: Primary aim 
 
First 
author 
(year) 
Quality 
rating 
Study design 
and 
methodology 
Recruitment 
location 
Sample 
size 
Age 
(mean) 
Type of 
MS (n) 
DMD Real/faux 
informatio
n 
Self-report 
or objective 
measure  
Outcome 
measure(s) 
Results 
Mohr et 
al., 
(1996) 
Moder
ate 
Questionnaire
: Baseline data 
from a pre-
post 
intervention 
study 
 
Outpatient 
clinics 
99 - Not 
specified 
Interferon 
beta-1b 
Real Objective DMD benefit 
understanding:  
Survey items from 
BSQ 
 
 
 
Relapse rate: 
 
Expected <10% reduction (‘overly 
pessimistic group’) = 4% patients 
Expected 10-30% reduction (‘accurate 
group’) = 39% patients 
Expected  >50% reduction (‘overly 
optimistic group’) = 57% patients 
Disease progression: 
 
Expected no change = 40% patients 
Expected slower progression = 26% 
patients 
Expected some restoration of function = 
29% patients 
Expected return to normal function = 4% 
patients 
 
Heesen 
et al., 
(2003) 
Weak Postal 
questionnaire: 
observational 
study 
MS patient 
organisation 
434 Wome
n=44; 
Men=4
3 
Not 
specified 
DMD not 
specified 
Real Self-report Understanding of 
overall DMD 
information: 3 
questions from 
13-item 
questionnaire 
52% of patients not informed at time of 
diagnosis; 
28% of patients informed after several 
months of diagnosis; 
71% of patients received sufficient 
information 
Heesen 
et al., 
(2004) 
Weak Postal 
questionnaire: 
observational 
study 
MS 
outpatient 
clinic 
169 44 RRMS (75);  
PPMS (75); 
Unclear 
(19) 
DMD not 
specified 
Real Objective  
 
 
 
DMD risk 
understanding: 
10 questions 
about DMD risks 
out maximum 19  
34% answers correct 
 
 
 
 
Self-report 
 
 
DMD risk 
understanding: 
VAS rating: 
63% of perceived knowledge  
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Perceived MS risk 
knowledge 
Vlahiotis 
et al., 
(2010) 
Weak  Postal survey: 
observational 
study 
American 
health 
insurance 
database 
2022 -                                                                                                                                                                                                                                                                                                                                                      PPMS (78); 
RRMS 
(1493); 
SPMS 
(213) 
Other (29); 
Unknown 
(209) 
 
Interferon-
beta 1a IM; 
Interferon 
beta 1a SC; 
Interferon-
beta 1b; 
Glatiramer 
acetate; 
Mitoxantron
e 
Real Self-report DMD benefit 
understanding: 
Survey questions 
DMD helps MS:
Females=79%; Males=72% 
 
Self-report Understanding of 
overall DMD 
information: 
Survey questions 
Awareness of other treatment options: 
Females= 85% ; Males = 80% 
Visser et 
al., 
(2011) 
Weak Postal survey: 
Observational 
study 
Hospitals; 
MS Patient 
organisation 
1371 Benign 
MS & 
RRMS = 
471; 
SPMS=
511; 
PPMS=
521 
Benign MS 
(251); 
RRMS 
(525); 
PPMS 
(120); 
SPMS 
(399);  
Unknown 
(76) 
DMD not 
specified 
Real Self-report 
 
 
 
 
 
 
 
 
 
 
Understanding of 
overall DMD 
information: 1 
item from 72-
item 
questionnaire; 
Enough 
treatment 
information 
received? 
  
 
 
 
'Taking first DMD' group: 
81% patients agree;  
9% patients neutral; 
10% patients disagree; 
 
'Changed DMD' group:  
84% patients agree; 
7% patients neutral; 
9% patients disagree 
'Stopped DMD' group:  
74% patients agree; 
15% patients neutral; 
11% patients disagree 
 
de Seze 
et al., 
(2012) 
Weak Postal 
questionnaire: 
Observational 
study 
Hospitals 
and 
community 
practise 
202 41 RRMS 
(202) 
Interferon-
beta 1a; 
Interferon-
beta 1b; 
Glatiramer 
acetate 
Real Self-report 
 
 
Understanding of 
overall DMD 
information: 
‘Well informed 
about 
treatment?’ 
Totally agree=35%; Partly agree=40%; 
Partly disagree=14%; Totally 
disagree=5%; No opinion=2% 
Self-report DMD benefit 
understanding 
Reduced relapse frequency with current 
DMD: 
Totally agree=50%; Partly agree=40%; 
Partly disagree=6%; Totally disagree=2%; 
No opinion=3% 
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Delay in treatment progression with 
current DMD: 
Totally agree=36%; Partly agree=50%; 
Partly disagree=9%; Totally disagree=2%; 
No opinion=5% 
 
Optimistic about MS due to DMD: 
Totally agree=28%; Partly agree=45%; 
Partly disagree=17%; Totally 
disagree=7%; No opinion=3% 
Hofmann 
et al., 
(2012) 
Moder
ate 
Postal 
questionnaire: 
Retrospective 
cohort study  
Database of 
hospitals 
and private 
clinics 
 
575 50 RRMS (49); 
PPMS (76); 
SPMS(258)
;  
Other (4); 
Unknown 
(188)  
Mitoxantron
e 
Real Objective 
 
 
DMD risk 
understanding: 
Risk choice from 4 
options about 
Mitoxantrone 
side-effects 
Leukaemia: 
Accurate risk choice = 40% patients 
Underestimated risk = 58% patients 
 
Cardiotoxicity: 
Accurate risk choice = 16% patients 
Underestimated risk = 82% patients 
 
Kӧpke et 
al., 
(2014) 
Strong Telephone 
and postal 
questionnaire:
Baseline data 
from Double-
blind RCT 
MS 
outpatient 
clinics 
192 37 CIS (27); 
RRMS 
(133); 
Unclear 
(32) 
Interferon-
beta; 
Glatiramer 
acetate 
Real Objective DMD risk 
understanding: 
‘Good risk 
knowledge’ 
defined as 
minimum 12 
answers from 
possible 19 
IG at baseline (n-93) 
35% patients with ‘good risk knowledge’  
 
CG at baseline (n=99):  
23% patients with ‘good risk knowledge’ 
 
Syed et 
al., 
(2014) 
Weak Structured 
questionnaire: 
Baseline data 
from 
longitudinal 
study 
Home 
support 
service 
2390 42 Not 
specified 
Interferon-
beta 1a 
Real Self-report 
 
Understanding of 
overall DMD 
information: 3 
items from survey 
44% of patients felt extremely well 
informed (n=1265) 
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Abolfazli 
et al., 
(2014) 
Weak Postal 
questionnaire: 
Observational 
study 
MS patient 
organisation 
425 34.3 Not 
specified 
Interferons Real Objective  
 
 
 
Understanding of 
overall DMD 
information 
Greater understanding associated with: 
High level of education (p=0.0010) 
Delay between onset of symptoms and 
definite MS (p=0.0190) 
Increased mobility (p=0.220) 
Younger age (p=0.030) 
Females (p=0.001) 
Ability to self-inject (p=0.003) 
 
Zimmer 
et al., 
(2015) 
Moder
ate 
Questionnaire
: Baseline data 
from pre-post 
intervention 
study 
MS Centre in 
hospital 
98 411 Not 
specified 
Fingolimod Real Objective 
 
 
 
 
 
 
 
Understanding of 
overall DMD 
information: 18-
item 
questionnaire 
Median score=6 out of 18 (IQR-=4-8) 
 
Greater understanding associated with: 
Females (p=0.02) 
Patients in a relationship compared to 
singles (p=0.03) 
 
 
Self-report Understanding of 
overall DMD 
information: 
VAS (0-10); 
Perception of 
being informed 
Number of patients with following 
scores (n-97): 
 
Score < 7 = 78 
Score =>7 = 19 
 
Absolute numbers reported, unless specified. Abbreviations: BSQ, Betaseron questionnaire; CG, control group; CIS, clinically isolated syndrome; DMD, disease-
modifying drug; IG, intervention group; MS, Multiple Sclerosis; PML, progressive multifocal leukoencephalopathy; PPMS, primary progressive multiple sclerosis; 
RCT, randomized controlled trial; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis; VAS=visual analogue scale. 
1=Median, 2=Range 
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Table 6. Patient and study characteristics, and themes from qualitative studies investigating MS patients’ understanding of DMD risks and benefits: Primary aim 
 
First author 
(year) 
Quality 
rating 
Study design 
and 
methodology 
Recruitment 
location 
Sample 
size 
Age 
(mean) 
Type of 
MS (n) 
DMD Real/faux 
informatio
n 
Self-
report or 
objective 
measure  
Outcome 
measure(s) 
Results 
Miller et al., 
(2001) 
- Qualitative 
interviews 
MS centre 15 28-552 RRMS (15) Interferon 
beta-1a 
Real Self-
report 
DMD benefit 
understanding: 
Themes from 
qualitative 
analysis 
Overestimating benefit of DMD: 
“I look at Avonex as my saviour. I 
probably expected a lot more from 
it than I was going to get, 
realistically” (pg. 242) 
 
Miller et al., 
(2012) 
- Qualitative 
interviews 
MS centre; 
Natalizumab 
infusion 
centre 
20 43 RRMS (20) Natalizum
ab 
Real Self-
report 
 
 
 
 
 
DMD risk 
understanding: 
Themes from 
qualitative 
analysis 
 
Low risk perception for DMD: 
“I didn’t feel that it was going to a 
big risk for me because I trust my 
doctors, and I don’t think they 
really pushed it if they didn’t feel 
confident” (pg. 41) 
 
High risk perception for DMD: 
“I’m sure anybody who goes on 
Tysabri from the moment they 
make that decision…worry about 
PML”. (pg. 42) 
“I was so afraid to try Tsyabri, you 
know, the warnings and the labels 
are just, they’re so scary.” (pg. 42) 
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Miller et al., 
(2006) 
- Qualitative 
interviews 
MS clinic 20 39-642 RRMS (20) Glatiramer 
acetate 
Real Self-
report 
DMD benefit  
Understanding: 
Themes from 
qualitative 
analysis  
 
Benefits of glatiramer acetate: 
“…the importance of getting on to 
these ABC drugs – Avonex, beta 
interferon and Copaxone – is to 
start as soon as you have 
symptoms” (pg. 39) 
“This way (injecting glatiramer 
acetate) I feel like I am doing 
something progressive to help it.” 
(pg. 39) 
“And I have researched the 
ingredients, and it is so natural” 
(pg. 40) 
Absolute numbers reported, unless specified. Abbreviations: DMD, Disease-modifying drug; MS, Multiple Sclerosis; PML, progressive multifocal 
leukoencephalopathy; RRMS, relapsing-remitting multiple sclerosis. 2=Range 
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Table 7. Patient and study characteristics, and results of quantitative studies investigating MS patients’ preferences for treatment risks and benefits: Secondary aim 
 
First 
author 
(year) 
Quality 
rating 
Study design 
and 
methodology 
Recruitment 
location 
Sample 
size 
Age 
(mean) 
Type of 
MS (n) 
DMD Real/faux 
informatio
n 
Self-report 
or objective 
measure  
Outcome 
measure(s) 
Results 
Prosser 
et al., 
(2002) 
Weak Survey: 
Observational 
study 
MS clinics 56 38 RRMS (56) Interferon-
beta 1a; 
Interferon-
beta 1b; 
Glatiramer 
acetate 
Faux Objective  Preferences for 
treatment 
benefits: 
Gamble question 
(drug with 
relapse-free days 
compared with 
dug offering 50% 
chance of 
immediate 
reduction but 50% 
chance of not 
working) 
Mean=14.6 relapse-free days 
 
Kasper et 
al., 
(2008) 
Strong Questionnaire
: Baseline data 
from RCT 
Newspapers; 
websites; 
national self-
help journal 
297 43 CIS (45); 
RRMS 
(153); 
PPMS (31); 
SPMS (59); 
Unclear (9) 
DMD not 
specified 
Real Self-report Preferences for 
treatment 
benefits: Likert 
scale 
Moderately optimistic towards 
current DMD:  
IG group at baseline =65% 
patients; 
CG group at baseline =62% 
patients 
 
Johnson 
et al., 
(2009) 
Moder
ate 
Survey: 
Observational 
study 
MS patient 
organisation
; 
Natalizumab 
clinical trial 
patients 
651 47 Not 
specified 
Natalizumab Real Objective  Preferences for 
treatment risk-
benefit profiles: 
Mean annual risk 
acceptable to 
patients 
Mean annual risk for ‘slow 
progression benefit’ (No. of 
relapses in next 5 years reduced 
from 4 to 1; disability 
progression delay from 5 to 8 
years) 
 
0.31% of PML death or 
disability; 
0.30% of death by liver failure; 
0.35% of death by leukaemia 
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Mean annual risk for ‘clinically 
relevant benefit’ (No. of 
relapses in next 5 years reduced 
from 4 to 1; disability 
progression delay from 3 to 5 
years) 
 
0.38% of PML death or 
disability; 
0.39% of death by liver failure; 
0.48% of death by leukaemia 
 
Mean annual risk for ‘largest 
tested benefit’ (No. of relapses 
in next 5 years reduced from 4 
to 0; disability progression 
delay from 1 to 8 years) 
 
0.74% of PML death or 
disability; 
1.02% of death by liver failure; 
1.08% of death by leukaemia 
 
 
Tur et al., 
(2013) 
Moder
ate 
Survey: 
Observational 
study 
MS centre; 
Hospital  
136  Nataliz
umab 
group = 
38; 
Other 
DMD 
group = 
39 
Not 
specified 
Natalizumab
; First-line 
DMDs 
Faux Objective  Preference for 
treatment risks: 
five risk levels for 
five presented 
therapeutic 
scenarios  
Mean scores for level of risks 
accepted: 
 
Patients taking Natalizumab 
(n=114): 
Very low risk=8.85; Low 
risk=8.49; Medium risk=7.47; 
High risk=4.29; Very high 
risk=3.01 
 
Patients taking any other DMD 
(n=22): 
Very low risk=7.50; Low 
risk=6.32; Medium risk=4.76; 
High risk=2.43; Very high 
risk=1.58 
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Abolfazli 
et al., 
2014 
Weak Questionnaire
: 
Observational 
study 
MS patient 
organisation 
425 34.3 Not 
specified 
Interferons Real Self-report 
 
 
Preference for 
treatment 
benefits: 
5-point Likert 
scale across 13 
questions 
Optimistic about current DMD = 
20% to 90% patients 
 
Optimistic about DMD 
associated with: 
Lack of functional problem 
(p=0.004) 
No MS family history (p=0.029) 
Knowledge of interferons 
(p=0.001) 
 
Wilson et 
al., 
(2014) 
Moder
ate 
Questionnaire
: Conjoint 
analysis 
MS clinic 289 42 RRMS 
(289) 
Interferons; 
Natalizumab
; Glatiramer 
acetate; 
Fingolimod; 
Rituximab 
Faux Objective Preference for 
treatment risk-
benefit profiles: 
Estimated 
acceptable risk 
for various DMD 
benefits  
For 1% risk of DMD severe side-
effects, patient preference for 
treatment decreased by 5 times 
 
 
         Objective Preference for 
treatment risks: 
Odds ratio  
Minor side effect: 
Headache flu=0.98 
Mood change=0.91 (p<0.001) 
 
Severe side effect:  
0.05% = 0.70 (p<0.001) 
0.10% = 0.60 (p<0.001) 
1%=0.22 (p<0.001) 
         Objective Preference for 
treatment 
benefits: Odds 
ratio 
Progression prevention:  
2 years=1 
4 years=1.36 (p<0.001) 
10 years=2.46 (p<0.001) 
 
Delay in relapse: 
1 year=1 
2 years=1.20 (p<0.001) 
5 years=1.53 (p<0.001) 
 
Symptom improvement:  
None=1        
Mild=1.75 (p<0.001) 
Substantial=3.68 (p<0.001) 
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Bruce et 
al., 2015 
Weak Questionnaire
: Probability 
discounting 
MS Clinics 77 Adhere
nt 
=43.26; 
Non-
adhere
nt 
=45.03 
RRMS Not 
specified 
Faux Objective Preferences for 
treatment risk-
benefit profiles: 
Medical Decision 
Making 
Questionnaire 
Chosen treatment benefit 
related to side-effect 
probability (p<.001) 
interaction between side effect 
and group (adherent and non-
adherent) for treatment 
benefits chosen (p<.001) 
 
Improbable side-effects predict 
treatment adherence = 83.1% 
Fox et 
al., 2015 
Weak Survey: 
Observational 
study 
North 
American 
Research 
Committee 
on Multiple 
Sclerosis 
(NARCOMS) 
Registry 
5446 52.7 Not 
specified 
Not 
specified 
Faux (cure 
for MS) 
and Real 
(Natalizum
ab) 
Objective Preference for 
treatment risk: 
Standard gamble 
paradigm 
Median risk tolerance for both 
scenarios=1:10,000 
 
Faux DMD scenario: 
No risk tolerance=23% 
Tolerate any risk=3.6% 
 
Faux DMD risk tolerance 
associated with: 
No disability=1:100,000 versus 
wheelchair-bound=1:1000 
(p<.0001); 
Male=1:2000 versus 
females=1:50,000 (p<.0001); 
Patients caring for 
dependents=1:100,000 versus 
not caring for dependents=1: 
10,000 (p<.0001); 
Patients taking DMD=1:50,000 
versus not taking 
DMD=1:50,000 (p=0.002); 
Patients taking 
Natalizumab=1:1,000 versus 
not taking 
Natalizumab=1:50,000 
(p<0.0001); 
Patients who routinely use 
seatbelt=1:50,000 verus those 
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who do not routinely use 
seatbelt=1:5000 (p=0.0007) 
 
Natalizumab scenario: 
No risk tolerance=15% 
Tolerate any risk=3.3% 
 
Natalizumab scenario risk 
tolerance associated with: 
No disability=1:100,000 versus 
wheelchair-bound=1:1000 
(p<0.0001); 
Male=1:2000 versus 
females=1:10,000 (p<.0001); 
Patients caring for 
dependents=1:50,000 versus 
not caring for dependents=1: 
10,000 (p=0.004); 
Patients taking 
Natalizumab=1:750 versus not 
taking Natalizumab=1:10,000 
(p<0.0001); 
Patients who routinely use 
seatbelt=1:10,000 versus those 
who do not routinely use 
seatbelt=1:1000 (p<0.0001) 
 
Wilson et 
al., 2015 
Weak Survey: 
Conjoint 
analysis 
MS Clinic 50 42.7 RRMS Glatiramer 
acetate; 
Interferon 
beta; 
Natalizumab
; Rituximab; 
Fingolimod; 
No-
treatment 
Faux Objective Preference for 
treatment risk  
Common adverse effects 
(significance to reference): 
Increased risk of 
infection=reference 
Injection-site reactions=-0.16  
Headaches, aches, flu=0.02   
Changes in mood=-0.82 
(p<0.001) 
 
Severe adverse effects: 
0%=reference 
1%= -1.15 (p<0.001) 
10%= =3.06 (p<0.001) 
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30%= -3.82 (p<0.001) 
         Objective 
 
Preference for 
treatment 
benefit: Conjoint 
analysis 
 
Clinical outcomes – β 
coefficient values compared 
with baseline treatment profile: 
Prevents symptom progression 
for 1 year=0.12 (p<0.001); 
Prevents one relapse per 
year=0.05; 
Prevents MRI progression for 1 
year=0.17 (p=0.002) 
 
Patient symptoms - β 
coefficient values compared 
with baseline treatment profile: 
Improved mildly=0.81 (p<0.001) 
Improved moderately=0.83 
(p<0.001) 
Improved rarely but 
substantially=1.03 (p<0.001) 
 
         Objective Preference for 
treatment risk-
benefit profiles: 
Conjoint analysis 
Patients willing to accept 30% 
adverse risk for 32 years 
prevention of disease 
progression  
 
Patients willing to accept 10% 
adverse risk for 25 years 
prevention of disease 
progression 
 
 
Absolute numbers reported, unless specified. Abbreviations: CIS, Clinically Isolated Syndrome, DMD, Disease-modifying drug; MS, Multiple Sclerosis; PML, 
progressive multifocal leukoencephalopathy; PPMS, primary progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary 
progressive multiple sclerosis; VAS, visual analogue scale. 1=Median, 2=Range 
 
 
